Sold out for the sixth consecutive year, the conference kicked off with its highest-attendance yet, featuring thought leadership sessions, multi-track small company presentations, one-on-one partnering meetings, and a networking lunch and reception.
Congratulations to Carissa Greenough and Lorikeet Therapeutics Pty Ltd who was selected to pitch at the Small Company presentations session – a chance to spotlight Australian innovation at this high-powered US forum.
And Carissa nailed it! Great presentation
Based in Melbourne, Lorikeet Therapeutics Pty Ltd is working on agonists of the melanocortin 5 receptor to drive insulin independent glucose uptake into skeletal muscle. Reducing the need for people living with Type 1 diabetes to use insulin!
These companies developing diabetes and cardiovascular innovations, including Endo Axiom, Inosi Therapeutics and Nanomedx – are lined up for partnering meetings and getting great feedback and follow ups, along with all the incidental networking opportunities peppered throughout the conference itself.
It’s all been made possible through MTPConnect’s MoU with Biocom California – one of the leading life science advocacy and industry associations in the US, representing over 1,800 member companies in the biotech, pharmaceutical, medical device, and diagnostics sectors.
Pictured above L-R at the Biocom Conference in La Jolla: Nicholas Hunt (Endo Axiom), Lauren Kelly (MTPConnect TTRA initiative), Filippa Shub (Inosi Therapeutics), Jeff Craig (Nanomedx), Stuart Dignam (MTPConnect)
